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Abstract
Background: Vardenafil (Levitra®) represents a potent and highly selective phosphodiesterase
type 5 (PDE5) inhibitor, which is established for treatment of various diseases. There are several
unpublished reports from patients stating that vardenafil has a considerable therapeutic effect on
their concomitant tinnitus. This pilot study was conducted to specifically assess the effect of
vardenafil in patients with chronic tinnitus.
Methods: This trial was based on a prospective, randomized, double-blind, placebo-controlled,
parallel group design. Fourty-two consecutive subjects with mon- or binaural chronic tinnitus
received 10 mg vardenafil (N = 21) or matching placebo tablets (N = 21) administered orally twice
a day over a period of 12 weeks. Clinical examination and data acquisition took place at each visit:
at baseline, after 4 weeks, after 12 weeks (end of treatment with study medication), and at non-
medicated follow-up after 16 weeks. Assessment of clinical effectiveness was based on a
standardized tinnitus questionnaire (TQ), the Short Form 36 health survey (SF-36), audiometric
measurements (mode, pitch and loudness of tinnitus; auditory thresholds) and biomarkers of
oxidative stress in patients' blood (malondialdehyde, protein carbonyl, homocysteine and total
antioxidative status). Therapeutic efficacy was evaluated by comparison of subjective and objective
parameters with baseline data between both treatment groups (ANCOVA).
Results: Vardenafil had no superior efficacy over placebo in the treatment of chronic tinnitus
during this study. The primary efficacy criterion 'TQ total score' failed to demonstrate significant
improvement compared to placebo. Subjective reports of TQ subscales and general quality of life
areas (SF-36), objective audiometric examinations as well as investigated biomarkers for oxidative
stress did not reveal any significant treatment effects. The safety profile was favorable and
consistent with that in other vardenafil studies.
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Conclusion: Although hypoxia and ischemia play a special role in the pathogenesis of tinnitus, the
PDE5-inhibitor-induced increase of nitric oxide-mediated vasodilatation exerted no specific
influence on tinnitus symptomatology. Considering the unclear risk of rarely associated hearing
impairment, systemic application of vardenafil or other PDE5 inhibitors prove to be not
appropriate for therapy of chronic tinnitus.
Background
Tinnitus is defined as subjective perception of noises with-
out existence of an objective sound source [1]. Chronic
tinnitus is an etiologically inconsistent, nosologically
complex symptom lasting for more than 3 months. Tinni-
tus-related distress, decompensation and resulting sec-
ondary symptomatology represent a worldwide major
health care problem with an enormous social and eco-
nomic demand for therapeutic treatment [2]. According
to epidemiological investigations, more than 37 million
Americans experience tinnitus, about 20% of them have
prolonged tinnitus requiring clinical intervention [3,4].
Patients with hearing impairment suffer significantly
more often from tinnitus than others; conversely, approx.
90% of all tinnitus patients are affected by impaired hear-
ing [5,6].
Noise (especially impulse noise), stress, ototoxic sub-
stances, sudden hearing loss as well as head and neck inju-
ries are factors that may contribute to the pathogenesis of
tinnitus [7-9]. Exposure to intense noise leads to a
decrease of oxygen partial pressure and blood flow in the
cochlea [10-12]. Ischemia and hypoxia are known to
greatly affect the function of cochlea [13,14]. Hence, ade-
quate microcirculation is essential to ensure optimal func-
tion of the inner ear. The blood flow into the cochlea is
derived from the basilar artery via anterior inferior cere-
bellar artery (AICA), labyrinthine artery and finally via
functional end arteries. The intra-cochlear diffusion dis-
tances are relatively long. Except for the basal part of coch-
lea, the main blood supply comes from spiral modiolar
artery (SMA). As pointed out by Tange [15], clinical fea-
tures vary according to the site of arterial obstruction.
Interruption of SMA leads to hair cell loss, but does not
affect the stria vascularis (SV). Circulation disorders in SV
cause general degeneration, but the sensory cells remain
intact. Occlusion of labyrinthine artery leads to almost
complete degeneration of the inner ear [16,17]. Ischemic
conditions impact the expression of a number of hypoxia
inducible factor 1 (HIF-1)-dependent genes, which are
involved in acute as well as chronic changes in circulation
and in the signal transduction [18,19]. Nitric oxide (NO),
a known mediator of vasodilatation and neurotransmis-
sion, is present in various parts of the cochlea [20]. NO is
the major endothelium-derived relaxing factor that inter-
acts with soluble guanylate cyclase generating cyclic gua-
nosine monophosphate (cGMP). cGMP activates protein
kinases and leads to relaxation of surrounding smooth
muscle, resulting in vasodilatation and increase in blood
flow [21,22].
Phosphodiesterase type 5 (PDE5) inhibitors are used for
the treatment of various cardiovascular, pulmonary, neu-
rological and urogenital diseases [23-25]. Vardenafil (Lev-
itra®) represents a potent and highly selective PDE5
inhibitor, which is established for therapy of erectile dys-
function (ED) and pulmonary arterial hypertension [26-
28]. There are several unpublished anecdotal reports from
male patients suffering from ED and concomitant tinni-
tus, stating that vardenafil has a considerable therapeutic
effect on their tinnitus. PDE5 inhibitors block the degra-
dation of cGMP by PDE5 [29]. As for NO-dependent
mechanisms, increased cGMP levels were shown to act on
pericytes, which ultimately leads to vasodilatation in the
SV improving blood supply to hair cells [30,31]. This
could constitute a mechanism contributing to the hypoth-
esized effect of PDE5 inhibitors on tinnitus.
Considering the causative role, which hypoxia/ischemia
and oxidative stress may play in the pathogenesis of tinni-
tus, the question aroused whether PDE5-inhibitor-
induced increase of cGMP and potentiated NO-depend-
ent vasodilatation exert a defined and specific influence
on tinnitus symptomatology. Therefore, we designed and
conducted this pilot study to specifically assess the effect
of vardenafil in patients with chronic tinnitus. The goal
was to evaluate therapeutic tinnitus improvement and to
show superior efficacy of vardenafil over placebo by
means of defined subjective and objective variables. Con-
cerning the latter, emphasis was placed on validated
blood parameters serving as biomarkers of oxidative
stress, namely malondialdehyde (MDA, indicator of lipid
oxidation [32]), protein carbonyl (PC, marker of protein
oxidation [33]), the total antioxidative status (TAS [34]),
and homocysteine (HCY, biomarker associated with vas-
cular disease [35]).
Methods
Study design and procedure
This phase II clinical study was based on a prospective,
randomized, double-blind, placebo-controlled, parallel
group design meeting good clinical practice criteria. The
study was conducted as an adaptive design with an
interim analysis after termination of 2 × 20 subjects. TheJournal of Negative Results in BioMedicine 2009, 8:3 http://www.jnrbm.com/content/8/1/3
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trial was conducted in accordance with the Declaration of
Helsinki and upon approval by the local ethical review
board. Before the study was started, all patients under-
went a baseline evaluation including detailed medical his-
tory, otorhinolaryngologic examination, full
neurootological diagnostics, electrocardiogram (ECG)
and blood tests. Within 1 week after screening visit V1, eli-
gible tinnitus patients were randomly assigned (by means
of computer-generated block randomization) to either
vardenafil or placebo group at randomization visit V2
(baseline). Subjects received treatment with study medica-
tion over a period of 12 weeks, i.e., from V2 to end of
treatment visit V4. Subsequently, they went into a non-
medicated follow-up for another 4 weeks until final fol-
low-up visit V5 after 16 weeks.
Study treatment consisted of 10 mg vardenafil tablets or
matching placebo tablets administered twice daily (bid)
orally. Study medication was supplied at V2 and after 4
weeks at interim visit V3 in carded blister pack dispensers
containing medications for 4 and 8 weeks respectively.
Tablets were to be swallowed with a glass of water
(approx. 200 ml) in the morning and evening, with a dos-
ing interval of approx. 12 hours. Subjects had to return the
whole medication packaging including empty blisters and
unused medication. The number of tablets returned was
counted in order to check compliance.
Clinical examination and data acquisition took place at
each visit. Subjective questionnaires concerning tinnitus
and quality of life were administered at baseline (V2),
during treatment (V3), at the end of treatment (V4), and
4 weeks after treatment with study medication (V5). Audi-
ometric measurements along with assessment of biomar-
kers of oxidative stress and vascular disease were also
performed from V2 to V5. Furthermore, patients were told
to immediately stop medication and show up for prema-
ture discontinuation (PD) visit in case of experienced
intolerance or adverse events (AEs) related to the study
medication.
Patients
Study participants were recruited from the patients of Tin-
nitus Center at the Charité Department of Otorhinolaryn-
gology (Oct 2006 to May 2007). A consecutive sample of
51 subjects with mon- or binaural chronic tinnitus was
enrolled in the screening process. Main inclusion criteria
were: male and female patients, age >18 to <65 years, tin-
nitus duration >3 months, chronic subjective cochlear tin-
nitus, no treatment of tinnitus within 4 weeks prior to
study entry, available linguistic and intellectual skills to
fill out the questionnaires.
Exclusion criteria comprised particular otologic findings
(acute or intermittent tinnitus, history of Menière's dis-
ease, tumors of the middle ear/inner ear/cerebellopontine
angle), specific diseases (history of malignancies, multiple
sclerosis, retinal disorders, liver/hematological/cardiovas-
cular diseases), pregnancy or breast-feeding women,
abnormal laboratory values (e.g., creatinine clearance <30
ml/min, elevation of aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) ≥ 3-fold upper limit of
normal), previous use of PDE5 inhibitors, special con-
comitant medication (nitrates or NO donors, alpha1-
adrenoceptor antagonists, potent inhibitors of cyto-
chrome P- 450 3A4), and any other concurrent treatment
of tinnitus during the trial (pharmacological and non-
pharmacological).
Trial data were analyzed using three populations: the
safety population, the intent-to-treat (ITT) population
and the per-protocol (PP) population. The safety popula-
tion was defined as all patients who received at least one
dose of randomized study medication and had any post-
randomization safety data. The ITT population included
all randomized patients who received at least one dose of
study medication and had at least one post-baseline
assessment in any clinical variable (psychometric data,
audiometric measurements). The PP population was
defined as a subgroup of the ITT population who com-
pleted the study as scheduled and for whom no major
protocol violations were observed (e.g., poor compliance,
insufficient drug exposure, prohibited concomitant medi-
cation).
After their written informed consent, 43 patients were
included in the study and randomized: 21 to vardenafil
and 22 to placebo group. Since one subject randomized to
placebo rejected participation, both the safety and the ITT
population finally included 21 patients of each treatment
group. The PP population consisted of 16 subjects receiv-
ing vardenafil and 19 subjects receiving placebo. A flow
chart of our study population is illustrated in Figure 1.
Subjective instruments for examination
Psychometric data were acquired by two established self-
evaluation instruments: a standardized tinnitus question-
naire (TQ) and the Short Form 36 health survey (SF-36).
We used TQ by Goebel and Hiller [36] to register tinnitus-
associated psychological and psychosocial complaints.
TQ by Goebel and Hiller is based on Hallam's TQ [37]
and it was specifically developed and validated for the
German population. Using TQ enables measuring the tin-
nitus impairment with six partially correlating factors
based on constructs of information-processing such as
irrational concepts, over-generalization and attitudes of
helplessness. Patients had to indicate how much each of
the 52 statements corresponded to their actual state on a
3-step category rating scale (true, partly true, not true).
The TQ total score as well as specific fields of distress wereJournal of Negative Results in BioMedicine 2009, 8:3 http://www.jnrbm.com/content/8/1/3
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assessed by means of subscales labeled: emotional dis-
tress, cognitive distress, intrusiveness, auditory perceptual
difficulties, sleep disturbances, and somatic complaints.
The resulting TQ total score (0–84 points) allows a subdi-
viding into four severity levels: low (1–30), moderate
(31–46), severe (47–59) and very severe impairment (60–
84 points). Tinnitus is considered to be 'compensated' at
a TQ level of = 46 (no secondary symptoms) and 'decom-
pensated' at a TQ level of = 47 (permanent annoyance and
psychological strain; accompanied by complaints like
depression, anxiety, impaired sleep and concentration).
The applied TQ has been sufficiently evaluated and is
regarded to be the best available method in Germany at
present to determine the tinnitus severity level [36].
The SF-36 questionnaire was applied as a well-established
assessment tool for general health care settings as well as
accepted methodology for the observation of clinical
course and therapy control in tinnitus [38,39]. The Ger-
man edition used was validated for German conditions
[40]. The SF-36 is interpreted as a health-related quality-
of-life (QoL) measurement with 36 category rating scaled
items, 8 scales summarizing subsets of these items and 2
summary measures (physical health, mental health).
Scores range from 0 to 100, with higher scores indicating
higher levels of functioning and associated QoL. Patients
were asked to rate the level of their present health condi-
tion. In order to provide a basis for the assessment of
achieved results, the scores were compared with mean val-
ues and standard deviations of a German normal sample.
Objective Parameters
Safety and tolerability of study medication was assessed
by vital signs (heart rate, blood pressure), 12-lead ECG,
and the following blood parameters: ALT, AST, creatinine,
glucose, creatine kinase (CK), creatine kinase muscle-
brain (CK-MB), potassium, and human chorionic gona-
dotropine (hCG). Safety analyses were performed on the
safety population. Treatment groups were compared with
respect to incidence rates of premature termination, treat-
ment-emergent adverse events (AEs), and abnormalities
of ECG and blood parameters.
Audiometric measurements were conducted to character-
ize the tinnitus and to investigate auditory thresholds at
tone exposures with varying frequencies from 0.125 kHz
to 10 kHz (pure tone audiogram). Tinnitus examination
comprised the determination of mode, pitch and loud-
ness of tinnitus. These individual tinnitus characteristics
were detected via a headset earphone device asking the
subject to indicate matching. Tinnitus loudness was
assessed by comparing the perceived tinnitus to the
known loudness of a defined acoustic stimulus presented
to the contralateral ear. The intensity of this comparative
tone or noise was identified, and the loudness was inter-
preted as the threshold in terms of dB at which the tinni-
tus is detected [41]. Tympanometric examinations were
performed to preclude pathological functioning in the
tympanum and the auditory meatus.
In addition, biomarkers were determined for objective
pharmacodynamic evaluation of oxidative stress and dis-
ease progression during therapy [35,42]. Therefore, the
levels of MDA, PC, TAS and HCY were measured in the
patients' blood. The plasma (EDTA) concentration of
MDA was determined by high performance liquid chro-
matography (HPLC) using a kit of fluorometric detection
supplied by Chromsystems (Munich, Germany). Serum
concentration of the PC was measured using the ZenTech
immuno-assay kit (Zenith Technology, Dunedin, New
Zealand). The TAS was determined in plasma (lithium
heparin) using the Randox assay (Crumlin, Antrim, UK).
The level of HCY was analyzed in serum using HPLC with
fluorometric detection after reduction and derivatization
(Recipe, Munich, Germany). The plasma/serum compo-
nent was separated (centrifugation at 3000 rpm for 10
min, within 30 min), and 0.5 ml aliquots were stored at -
20°C until analysis.
Statistical Analysis
Means ± standard deviations (SD) were calculated for all
parameters measured. The primary efficacy analysis was
based on the TQ score in the ITT sample. Inferential statis-
tics utilized the last observation carried forward (LOCF)
value, i.e., the score observed at the last visit under treat-
ment (or PD). Statistical analysis was based on an analysis
Flow chart of study population Figure 1
Flow chart of study population.
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of covariance (ANCOVA) with baseline as covariate and
the LOCF value as dependent variable. Factor was 'treat-
ment'. The homogeneity of regression slopes was tested.
Analysis was repeated for the PP population. The second-
ary efficacy and outcome variables were as follows: QoL
(SF-36), audiometric data, blood parameters of oxidative
stress, safety and tolerability parameters. These variables
were also analyzed via descriptive statistics and the
ANCOVA model. It was decided to determine the study
with conclusion of efficacy when the actual p-value was ≤
0.0233. If the p-value exceeded 0.5, no efficacy conclusion
would be drawn from the data and the study would stop.
P-values of >0.0233 – 0.5 were considered to plan a sec-
ond study.
Results
Baseline patient characteristics
Relevant general and otologic characteristics of the
patients are presented in Table 1. Patients assigned to both
treatment groups were comparable with regard to baseline
characteristics including race (all Caucasian), sex-ratio,
age, socio-demographic criteria, weight and body-mass-
index (BMI). Regarding risk factors and concomitant dis-
eases (High Level Terms, MedDRA version 10.0), vardena-
fil and control group showed similar smoking and
drinking habits, 14 subjects had systemic arterial hyper-
tension and 8 were diagnosed with psychiatric disorders
(depression, anxiety). Audiometric parameters revealed
no significant differences concerning tinnitus variables
and degree of tinnitus annoyance. Altogether, 17 subjects
suffered from a unilateral tinnitus, 25 from a bilateral one.
Tinnitus was compensated in 27 patients (cT) with low to
moderate impairment (mean TQ score = 22.5), and
decompensated in 15 patients (dT) with severe to very
severe impairment (mean TQ score = 60). The pre-thera-
peutic course of tinnitus was constant in 71% and pro-
gressive in 29% of study participants. The mean pre-
existing tinnitus duration was 6 years (range, 8 months to
28 years). A concomitant hearing loss was prevalent in
about 90% of all patients. Normacusis was not seen in
verum group, but in 4 placebo subjects (8 tinnitus ears).
Table 1: Major baseline characteristics.
Characteristics All patients
(N = 42)
Vardenafil
(N = 21)
Placebo
(N = 21)
Gender
Male 30 (71%) 14 (67%) 16 (76%)
Female 12 (29%) 7 (33%) 5 (24%)
Age, years (mean ± SD) 49.0 ± 10.2 51.3 ± 10.0 46.7 ± 10.2
Body weight, kg (mean ± SD) 81.6 ± 17.0 82.6 ± 19.2 80.6 ± 14.8
BMI, kg/m2 (mean ± SD) 26.5 ± 3.9 27.1 ± 4.2 25.9 ± 3.5
Non-smokers 27 (64%) 16 (76%) 11 (52%)
Smokers 15 (36%) 5 (24%) 10 (48%)
Pack-year historya (mean ± SD) 17.3 ± 10.8 19.9 ± 10.7 15.9 ± 11.3
Current alcohol consumption
Abstinent 15 (36%) 8 (38%) 7 (33%)
Light/moderate (≤ 2 unitsb per day) 27 (64%) 13 (62%) 14 (67%)
Tinnitus duration, years (mean ± SD) 6 ± 5 7 ± 6 5 ± 3
Course of tinnitus
Constant 30 (71%) 17 (81%) 13 (62%)
Progressive 12 (29%) 4 (19%) 8 (38%)
Tinnitus prevalence
Ears without tinnitus 17 (20%) 9 (21%) 8 (19%)
Ears with tinnitus 67 (80%) 33 (79%) 34 (81%)
Tonal type 60 (90%) 29 (88%) 30 (88%)
Noise type 7 (10%) 4 (12%) 4 (12%)
Hearing level in tinnitus earsc
Normacusis (<20 dB) 8 (12%) 0 (0%) 8 (23%)
Mild hearing loss (20–40 dB) 49 (73%) 28 (85%) 21 (62%)
Moderate hearing loss (41–60 dB) 9 (14%) 4 (12%) 5 (15%)
Severe hearing loss (>60 dB) 1 (1%) 1 (3%) 0 (0%)
Tinnitus annoyance
cT (TQ total score ≤ 46) 27 (64%) 13 (62%) 14 (67%)
dT (TQ total score ≥ 47) 15 (36%) 8 (38%) 7 (33%)
a(number of years smoking) × (number of cigarettes per day)/20; bOne unit = one glass of wine or beer; camount of mean hearing loss as detected 
in pure tone audiogram (1, 2, 3, 4 kHz); cT – compensated tinnitus, dT – decompensated tinnitus, TQ – tinnitus questionnaire.
Data are expressed as number and percentage of subjects, unless otherwise noted.Journal of Negative Results in BioMedicine 2009, 8:3 http://www.jnrbm.com/content/8/1/3
Page 6 of 12
(page number not for citation purposes)
Treatment compliance and safety analysis
Study medication was taken for 77 ± 21 days on average
(range 3–90 days, median 84 days = 12 weeks) without
major differences between treatment duration in the var-
denafil and placebo group (72 ± 26 vs. 81 ± 13 days). Pill
count revealed that the average number of doses taken by
all subjects was 148 ± 44 doses (range 4–175 doses,
median 167 doses = 2 × 1 tablet per day). Eighty-one per-
cent of all patients had a study drug intake compliance
rate of 80 to 100%; 90.5% of placebo and 85.8% of verum
group subjects were compliant within the tolerated range
(80–120%). Descriptive data of adherence and compli-
ance with study medication showed no discernible differ-
ences between active treatment and placebo group.
Concerning safety, there were no clinically important dif-
ferences between treatment groups for vital signs or labo-
ratory parameters at any time point. Mean baseline values
of blood pressure and pulse did not change under ther-
apy. ECG findings, cardiac measures and all other param-
eters investigated in this study raised no clinical concerns.
Distribution of AEs (Preferred Terms, MedDRA version
10.0) and drop-outs are listed in Table 2. Treatment-emer-
gent AEs were reported by 38% of vardenafil and 14% of
placebo patients. The most common complaints were
headache, diarrhea, and nasal congestion. 28.5% of var-
denafil and 9.5% of placebo patients experienced non-
serious AEs considered drug-related, which led to PD in 4
vardenafil subjects (1 woman with diarrhea, 1 woman
with intolerable heat sensation, 1 man with prolonged
penile erection, and 1 man with flushed face and nasal
mucosal swelling) and in 1 placebo subject (1 man with
dizziness, headache, and nausea). In all patients with PD
due to medication, the experienced symptoms resolved
within one week after discontinuation of the study drug.
Serious or fatal AEs were not observed.
Efficacy analysis
TQ
The initial mean TQ scores were at the same level in verum
and control group (34.9 and 36.9). After 16 weeks
(LOCF), placebo-treated patients reported a slight
improvement by 1.7 points, but vardenafil-treated sub-
jects showed a mean deterioration by 2 points on average
(Table 3). However, within- and between-groups differ-
ences were clinically not relevant. The course of TQ total
scores (LS-means) from V2 to V5 with LOCF in both treat-
ment groups is shown in Figure 2. The analysis of ITT sam-
ple did not demonstrate any treatment effects. The
analysis of the PP sample with 16 verum and 19 placebo
subjects yielded consistent results. Effects remained the
same when reference was made to the 12-week active
treatment period at V4, when subjects were still under
drug exposure.
In addition, the groups were subdivided into patients with
cT (14 placebo and 13 vardenafil subjects) and dT (7 pla-
cebo and 8 vardenafil subjects) according to their different
degree of tinnitus severity. The ANCOVA did not reveal
any significant effects of vardenafil on cT or dT patients
(data not shown).
TQ subscales
With regard to TQ subscales, none of the various domains
of tinnitus-associated complaints underwent substantial
changes during therapy (Table 3). While all TQ sub-scores
showed slight improvements or maintained stable under
placebo treatment, there was a tendency for minor deteri-
orations under vardenafil medication, especially for the
subscales emotional distress and auditory perceptual dif-
ficulties. However, all differences in changes from base-
line were statistically not significant.
SF-36
The general health status SF-36 did not show any signifi-
cant changes (Table 4). Comparison of average baseline
values with the German norm values indicated a relatively
reduced condition with regard to emotional and social
competence as well as problems in fulfilling the own
expectations (role – physical). The ANCOVA results did
not reveal any treatment effects on one of the QoL areas.
Audiometric data
The audiometric examinations revealed no substantial
changes. Tinnitus pitch was determined in both ears and
ranged between 0.125 and 10 kHz. The pre-therapeutic
mean tinnitus frequency was 4 kHz in vardenafil and 6
kHz in placebo subjects. At week 16 (LOCF), tinnitus
pitch had remained stable in placebo patients, but
increased in vardenafil patients to 6 kHz. However, there
was a considerable inter-individual variability, even when
the relative coefficient of variation was used (adjusted for
Table 2: Incidence rates of adverse events (AEs) and premature 
discontinuation.
Vardenafil
(N = 21)
Placebo
(N = 21)
Treatment-emergent AEs 8 (38.1%) 3 (14.3%)
Drug-related AEs 6 (28.5%) 2 (9.5%)
- Headache 1 (4.75%) 2 (9.5%)
- Diarrhea 2 (9.5%) 0 (0%)
- Nasal congestion 2 (9.5%) 0 (0%)
- Prolonged penile erection 1 (4.75%) 0 (0%)
Serious or fatal AEs 0 (0%) 0 (0%)
Premature discontinuation 5 (23.8%) 2 (9.5%)
- due to drug-related AEs 4 (19.05%) 1 (4.75%)
- due to poor compliance 1 (4.75%) 1 (4.75%)
Data are expressed as number and percentage of subjects in both 
treatment groups.Journal of Negative Results in BioMedicine 2009, 8:3 http://www.jnrbm.com/content/8/1/3
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sample size). Although descriptive statistics revealed dif-
ferent changes in both groups, exploratory ANCOVA did
not demonstrate a significant vardenafil treatment effect.
The average tinnitus loudness remained relatively con-
stant. Again, there was a considerable between-subject
variability ranging from 2 to 110 dB SPL (sound pressure
level). In the placebo group, the average loudness slightly
increased in tinnitus-affected right ears (33 to 35 dB SPL)
and remained stable in the left ears (38 dB SPL). Vardena-
fil-treated subjects showed a marginal increase by 1 dB
SPL on average in right and left tinnitus ears (41 to 42 and
44 to 45 dB SPL, respectively).
As detected in the pure tone audiograms (0.125 to 10
kHz) of the patients, study medication did not result in
any therapy-related impairment of hearing function.
There was a pretherapeutic discrepancy between both
treatment groups with the mean pantonal hearing loss
being about 5 dB higher in the vardenafil group (28 dB)
than in the placebo group (23 dB). However, the course of
intra- and posttherapeutic values at all frequencies were
comparable in verum and placebo patients without signif-
icant differences or trends. The particular hearing thresh-
olds for both ears and treatment groups by visit (ITT) are
displayed in Figure 3. The hearing thresholds did not
show any significant changes.
Oxidative stress parameters in blood
The mean baseline values of MDA, TAS, PC and HCY are
shown in Table 5. The mean baseline values were within
the normal reference ranges and did not differ between
both groups. The ANCOVA did not reveal any treatment
effects in both groups from baseline to week 16 (LOCF)
(ITT).
Four patients of the vardenafil group and 3 patients of the
placebo group exposed HCY levels in serum (12–21
μmol/l) that are above the normal reference range regard-
ing age and gender [43]. To exclude any influence of these
high HCY values on tinnitus severity and hearing func-
tion, the whole statistics were repeated without the values
of these 7 subjects. The analysis resulted in the same slight
changes in the total score and subscores of the TQ as well
as in the same audiometric findings like described above.
ANCOVA did not reveal any treatment effects (data not
shown).
Discussion
Tinnitus is a complex symptom, whose specific patho-
physiological connections and interactions are still not
completely understood. Conditions like noise exposure,
cardiovascular diseases, arterial hypertension, hyperlipo-
proteinemia, diabetes mellitus, or stress overload might
cause hearing loss and tinnitus via changes of cochlear
microcirculation with consecutive long-term impairment
Table 3: TQ total score with subscores (mean ± SD) at baseline and at week 16 (LOCF) including ANCOVA results from baseline to 
week 16 (LOCF) of ITT samples.
Vardenafil (N = 21) Placebo (N = 21)
TQ Baseline LOCF Changes Baseline LOCF Changes p-valuea
Total score 34.9 ± 20.0 36.9 ± 21.3 2.0 ± 7.9 36.9 ± 21.0 35.2 ± 22.4 -1.7 ± 12.4 0.29
Subscores
Emotional distress
9.1 ± 5.8 9.7 ± 6.5 0.6 ± 3.3 10.0 ± 7.1 9.3 ± 7.2 -0.7 ± 4.0 0.29
Cognitive distress 6.6 ± 4.6 6.6 ± 4.8 0 ± 1.8 7.0 ± 5.2 6.4 ± 5.5 -0.6 ± 3.3 0.52
Intrusiveness of tinnitus 9.8 ± 3.8 9.9 ± 3.6 0.1 ± 2.2 9.4 ± 3.9 8.9 ± 4.3 -0.5 ± 2.9 0.34
Aud. perc. difficultiesb 4.6 ± 4.5 5.7 ± 4.1 1.1 ± 2.4 5.3 ± 3.4 5.5 ± 4.1 0.2 ± 2.7 0.26
Sleep disturbances 3.0 ± 2.6 3.0 ± 2.8 0 ± 1.2 3.2 ± 2.8 3.3 ± 3.0 0.1 ± 1.0 0.88
Somatic complaints 1.9 ± 2.1 2.0 ± 2.3 0.1 ± 1.0 1.9 ± 1.7 1.9 ± 1.8 0 ± 1.5 0.81
aF-Test, ANCOVA; bAuditory perceptual difficulties
Time course of total TQ scores from baseline to week 16  with LOCF evaluated in vardenafil and placebo groups Figure 2
Time course of total TQ scores from baseline to 
week 16 with LOCF evaluated in vardenafil and pla-
cebo groups. Given are the LS-means and 95% confidence 
intervals of the ITT population.
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of blood circulation in the inner ear. Advances in methods
of examining the cochlea and the human brain have
increased specific knowledge about the origins of tinnitus
[44,45]. Though, in many cases the actual cause remains
unknown, somatic and psychosocial factors seem to be
involved in its occurrence, centralization, chronification
and possible decompensation. Due to this complexity,
there is still no standard drug available for pharmacologi-
cal treatment of "the" tinnitus. Our results demonstrate
no difference in the treatment efficacy of chronic tinnitus
between vardenafil and placebo. The primary efficacy cri-
terion 'TQ total score' failed to demonstrate significant
improvement compared to placebo in this study. This was
also true for patients with high or low severity of tinnitus
(dT, cT). Furthermore, the secondary efficacy analyses did
not support the hypothesis that vardenafil could have
beneficial therapeutic influence. Subjective reports of TQ
subscales and general QoL areas (SF-36), objective audio-
metric examinations as well as investigated biomarkers for
oxidative stress did not reveal any significant treatment
effects.
Oxidative/nitrosative stress is recognized to be a promi-
nent feature of many acute and chronic diseases and their
progression [42]. In contrast, in the present study, none of
the biomarkers of oxidative stress that were measured in
the blood of patients with chronic tinnitus indicated sta-
tistically significant changes. Thus, the treatment of
patients suffering from chronic tinnitus did not result in
considerable modifications of the overall lipid and pro-
tein oxidation level, the total antioxidant capacity, or HCY
concentration. HCY served as biomarker of oxidative
stress in vascular tissue and is known to be associated with
an increased risk of thrombosis and atherosclerosis [35].
However, exclusion of patients with high HCY values in
serum offered consistent results without treatment effects
or influence on tinnitus severity and hearing function.
Regarding biomarker interpretation, some aspects have to
be taken into account, e.g. different degrees of inter- and
intraindividual variability and sensitivity, unknown
amount of confounding and modifying factors, as well as
uncertain specificity for different diseases. In patients with
acute tinnitus, low NO levels were found in brain circula-
tion reflux blood taken from the internal jugular vein, and
a general cerebro-vascular endothelial dysfunction was
discussed [46]. Furthermore, this study detected increased
plasma levels of oxidative markers, which could not be
confirmed in our patients with chronic tinnitus, where the
blood was taken from the brachial veins. Therefore, global
criteria of oxidative stress may not reflect specific oxida-
tive stress in regions of the brain and inner ear.
Even if the investigated PDE5 inhibitor failed to show effi-
cacy for treatment of chronic tinnitus, there is experimen-
tal evidence that the regional cochlear blood flow is
actively regulated by the NO-system [20-22,47]. NO is
produced by vascular endothelium and acts on the vascu-
lar smooth muscle to dilate the vessels and increase blood
flow. In cochlear vasculature, NO plays a pivotal role in
the regulation of vascular tone [21,22]. NO stimulates the
soluble guanylate cyclase with subsequent cGMP forma-
tion, which activates protein kinases and leads to dephos-
phorylation of the myosin light chain [47]. Hence, drugs
acting through the NO pathway should be highly capable
Table 4: SF-36 subsets (mean ± SD) at baseline and at week 16 (LOCF) including ANCOVA results from baseline to week 16 (LOCF) 
of ITT samples.
SF-36 subsets Vardenafil (N = 21) Placebo (N = 21)
Baseline LOCF Changes Baseline LOCF Changes p-valuea
Physical funct.b
(85.7 ± 22.1)
80.5 ± 19.9 74.3 ± 28.0 -6.3 ± 15.0 77.0 ± 26.9 77.0 ± 27.6 0.0 ± 14.0 0.18
Role-physical
(83.7 ± 31.7)
58.8 ± 41.6 55.0 ± 44.9 -3.8 ± 40.0 63.1 ± 44.4 51.2 ± 47.1 -12 ± 33.2 0.53
Bodily pain
(79.1 ± 27.4)
60.1 ± 29.9 51.3 ± 31.4 -8.8 ± 17.4 65.2 ± 28.4 62.9 ± 30.4 -2.3 ± 19.9 0.21
General health
(68.1 ± 20.2)
59.5 ± 22.8 55.6 ± 25.4 -3.8 ± 10.9 49.1 ± 20.3 48.0 ± 22.4 -1.2 ± 12.0 0.52
Vitality
(63.3 ± 18.5)
55.3 ± 21.6 52.3 ± 22.6 -3.0 ± 12.1 43.8 ± 20.1 42.5 ± 25.3 -1.2 ± 13.9 0.75
Social funct.b
(88.8 ± 18.4)
73.2 ± 22.1 71.4 ± 24.4 -1.8 ± 9.9 62.5 ± 32.8 64.9 ± 33.0 2.4 ± 24.2 0.70
Role-emotional
(90.4 ± 25.6)
63.1 ± 42.9 61.4 ± 46.2 -1.7 ± 47.8 60.4 ± 43.0 54.0 ± 44.1 -6.4 ± 41.8 0.64
Mental health
(73.9 ± 16.4)
67.0 ± 19.2 61.6 ± 21.6 -5.4 ± 13.6 52.0 ± 20.4 51.0 ± 22.9 -1.1 ± 14.3 0.59
aF-Test, ANCOVA; bfunctioning.
In the left column, average German norms (± SD) are given in brackets.Journal of Negative Results in BioMedicine 2009, 8:3 http://www.jnrbm.com/content/8/1/3
Page 9 of 12
(page number not for citation purposes)
of improving cochlear microcirculation. However, the
mechanism of action of the PDE5 inhibitor used in the
present study did not exert efficacy in respect to the mech-
anisms involved in chronic tinnitus. Thus, improving
cochlear blood supply seems not be effective in the treat-
ment of chronic inner ear disorders. The associated coch-
lear and central changes in chronic tinnitus are
presumably already permanent and for that reason irre-
versible by NO. Conceivably, approaches for integration
into acute tinnitus therapy could turn out to be more
promising. Furthermore, various causes may represent the
underlying pathophysiology of tinnitus. Sensorineural
Audiometric hearing thresholds from baseline to week 16 evaluated in left and right ears of vardenafil and placebo groups (ITT) Figure 3
Audiometric hearing thresholds from baseline to week 16 evaluated in left and right ears of vardenafil and pla-
cebo groups (ITT). For the sake of clarity, week 4 and LOCF data as well as whiskers are not shown.
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Table 5: Baseline values of oxidative stress-related parameters measured in blood of vardenafil- and placebo-treated patients (mean ± 
SD).
Blood parameter Vardenafil (N = 21) Placebo (N = 21)
Malondialdehyde (μmol/l) 0.07 ± 0.02 0.07 ± 0.02
Protein carbonyl (nmol/mg protein) 0.32 ± 0.12 0.29 ± 0.12
Total antioxidative status (mmol/l) 1.42 ± 0.30 1.45 ± 0.14
Homocysteine (μmol/l) 10.59 ± 3.52 9.27 ± 2.40Journal of Negative Results in BioMedicine 2009, 8:3 http://www.jnrbm.com/content/8/1/3
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tinnitus is subdivided into motor, transduction, transfor-
mation, and extra-sensory tinnitus (type I-IV) [48]. Irreg-
ular release of neurotransmitters is believed to be involved
in transformation tinnitus, whereas vascular disorders in
the SV or cochlea may play a potential role in extra-sen-
sory tinnitus [49]. Since diagnostics are still not available
to precisely determine the patient's special subtype of sen-
sorineural tinnitus, non-existence of vascular genesis
obviously can not result in an adequate effect of vardena-
fil therapy.
Moreover, one might speculate that a 12-week period of
drug application could have been too short or underdosed
for treatment success. There is, however, evidence of effi-
cacy for the long-term use of vardenafil 10 mg bid at 12 hr
intervals [50] with sufficient therapeutic effect on ED
[26,27]. The terminal half-life of vardenafil is approx. 4
hours. Therefore, the bi-daily regimen chosen was
unlikely to cause cumulation. Since the pharmacody-
namic effect of PDE5 inhibition is generally the same irre-
spective of the clinical indication, the selected dosage
regimen exerted efficacy around the clock. Though, the
missing effect of vardenafil on tinnitus symptoms is pos-
sibly due to the insufficient concentration of vardenafil in
the inner ear. It is known that various medicaments
applied systemically often fail to reach cochlear structures
at adequate concentration and therefore, to achieve or
increase therapeutic effects in the inner ear drugs have to
be administered locally, for instance near or via the round
window membrane [51,52].
With respect to safety of vardenafil in subjects diagnosed
with tinnitus, no serious AEs were noticed. There were no
deaths or clinically significant events like myocardial inf-
arction or visual disturbances. Detected drug-related AEs
were previously known from other studies or arise from
the mechanism of vardenafil action. PDE5 inhibitors
block the PDE5 induced degradation of cGMP [29] and
thus lead to relaxation of smooth muscle cells lining the
blood vessels, for instance those supplying the corpora
cavernosa of the penis [53]. Conceivably, the increasing
blood flow accounts for prolonged penile erection and
nasal mucosal swelling in altogether 3 of our patients. All
AEs were typical, generally transient, or disappeared after
discontinuation of the study drug. Our AE profile was
consistent with the safety profile in vardenafil studies on
other indications. Prevalent drug-related AEs with an inci-
dence of 2% or more are headache, flushing, rhinitis, dys-
pepsia, and dizziness [26,54]. Vardenafil given at 20 mg
per day was shown to be safe for daily on-demand admin-
istration for longer periods of time [50].
Concerning our objective audiological investigations, the
obtained results revealed no significant influence of var-
denafil on average hearing thresholds or tinnitus parame-
ters. However, mean tinnitus pitch remained stable in
placebo patients, but slightly increased in verum subjects.
Unfortunately, during our trial in 2007, there were first
rare announcements of sudden decrease or loss of hearing
in ED patients receiving PDE5 inhibitor therapy. Mean-
while, according to the US Food and Drug Administration
at least 29 cases of such hearing impairment have
occurred during post-marketing experience with all PDE5
inhibitors including vardenafil, with or without concom-
itant vestibular manifestations [55]. Hearing loss was uni-
lateral in most cases, and temporary in about one-third of
the patients. In one case, a 44-year-old man experienced
permanent, bilateral sensorineural deafness 15 days after
initiating therapy with the PDE5 inhibitor sildenafil; the
patient did not have any prior or current risk factors for
ototoxicity [56]. On the other hand, PDE5 inhibitors have
been used worldwide so far by more than 40 million
patients with ED and pulmonary arterial hypertension
without otic side effects [23,27,28]. It is unclear whether
these effects are directly related to PDE5 inhibitors or
attributed to other factors (e.g., patient's underlying med-
ical condition, concomitant use of other ototoxic drugs).
However, a strong temporal relationship has been
observed between the use of PDE5 inhibitors and the
onset of hearing impairment in the reported cases. The
'precautions' and 'adverse reactions' sections of the
approved product labeling had to be revised [50]. Due to
these rare events, clinicians must advise patients about the
possibility of hearing loss in case of intended vardenafil
therapy. Patients should be instructed to discontinue
PDE5 inhibitor treatment and seek medical attention
immediately if sudden hearing loss occurs.
Conclusion
In patients with chronic tinnitus, a 12-week trial with var-
denafil tablets 10 mg bid was not superior over placebo.
Our data did not show any significant treatment effects.
The safety profile was favorable and consistent with that
of other vardenafil studies. In spite of the particular role,
which hypoxia and ischemia play in the pathogenesis of
tinnitus, the PDE5-inhibitor-induced increase of cGMP
and NO-dependent vasodilatation exerted no specific
influence on tinnitus symptomatology. Considering our
results and other studies with an unclear risk of rarely
associated hearing impairment, systemic application of
vardenafil or other PDE5 inhibitors prove to be inappro-
priate for therapy of chronic tinnitus. However, this is the
only study of a PDE5 inhibitor that we are aware of having
systematically assessed pure tone audiograms. This was
performed in a double-blind manner versus placebo in a
population of tinnitus patients. Given the above men-
tioned reports of sudden hearing loss in timely associa-
tion with PDE5 inhibitors, it may be an important finding
from this study that vardenafil did not cause statistically
significant impairment of hearing thresholds in compari-Journal of Negative Results in BioMedicine 2009, 8:3 http://www.jnrbm.com/content/8/1/3
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son with placebo in this population at risk according to
the objective measures used.
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